Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...
Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback